Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedNon-significant editorial updates were made: the page now explains that publications are automatically filled from PubMed and the revision was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoChange DetectedDeleted the generic government funding operating status notice from the page. The study content, eligibility criteria, and contacts remain unchanged.SummaryDifference0.1%

- Check33 days agoChange DetectedThe Locations section now lists 'Tainan, Taiwan, 704' and 'Tainan, Taiwan, 73657', replacing 'Tainan City, Taiwan, 704' and 'Tainan City, Taiwan, 73657'.SummaryDifference0.0%

- Check47 days agoChange DetectedNo additions or deletions were detected on the Study Details page for NCT04194944 LIBRETTO-431; core content such as the Study Title, design, interventions, primary and secondary outcomes, eligibility criteria, and Locations remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check55 days agoChange DetectedNo significant changes to core content or time-sensitive information detected; updates appear to be only date-related entries and deletions of some earlier dates.SummaryDifference0.2%

- Check69 days agoChange Detected- Location designation updated from Rhône-Alpes to Auvergne-Rhône-Alpes for Lyon with postal code unchanged. - Revision bumped from v3.1.0 to v3.2.0. - Added general government-operating-status notice (lower impact).SummaryDifference4%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.